AwaDoc, the WhatsApp-based health platform co-founded by Nigerian physician and media personality Chinonso Fidelis Egemba, has processed more than 200 million health queries since launch. Egemba, better known by his “Aproko Doctor” persona, announced the milestone in a LinkedIn post, crediting organic demand rather than paid acquisition for the volume.
Egemba co-founded AwaDoc with Jesse Benedict in April 2025, building on nearly a decade of health content he had built under the Aproko Doctor brand across X, Instagram, TikTok, and YouTube, where his combined following sits close to seven million. The platform runs as an AI-powered symptom checker and health-guidance tool delivered through WhatsApp, a deliberate choice to meet Nigerian users on infrastructure they already use rather than asking them to download a new app.
A WhatsApp-First Bet on Nigeria’s Care Gap
That distribution decision matters more in Nigeria than it would almost anywhere else. Fewer than 5% of Nigerians carry any form of health insurance, and the majority of those who do get it through an employer rather than buying it directly. Combined with a doctor-to-patient ratio that ranks among the worst globally, that leaves most Nigerians choosing between an unaffordable clinic visit, a risky self-diagnosis, or, increasingly, a WhatsApp message to a chatbot. AwaDoc is positioning itself squarely in that gap, though Egemba has been explicit that the platform is not a telemedicine service and does not aim to replace a doctor visit.
The bet mirrors a pattern that has worked elsewhere in Nigerian tech: build on top of infrastructure people already trust rather than asking them to adopt something new. Mobile money succeeded in Nigeria in part because it rode existing phone ownership rather than requiring new hardware. AwaDoc is applying the same logic to healthcare, using WhatsApp’s near-universal penetration to sidestep the cost and friction of building and marketing a standalone app. For a platform trying to reach users who may never have used a health app before, that is a meaningfully lower barrier to a first interaction.
What 200 Million Queries Actually Says About Demand
In his post, Egemba argued that the 200 million figure represents more than usage volume. He described it as evidence of what health information Africans actually need and how they ask for it, distinguishing AwaDoc’s approach from a basic chatbot by pointing to features that track context across a conversation rather than answering single symptoms in isolation. The platform’s marketing has also referenced community screening efforts that it says have flagged cancers that might otherwise have gone undetected, though AwaDoc has not published independently verified data on diagnostic accuracy or outcomes at that scale.
Nigeria’s broader healthtech sector has drawn steady, if modest, institutional capital over the past two years, which puts AwaDoc’s organic growth in sharper relief. Nigerian healthtech firm NucleusIS rebranded as RIGO while chasing a slice of Africa’s healthcare market, projected to reach $259 billion by 2030, and diagnostics network MDaaS Global closed a $3 million pre-series A round to expand its clinic infrastructure. Development finance has also entered the space: Japan’s JICA backed African healthtech startup CarePoint with a $3 million loan as part of a wider push into the continent’s care gap. Most of those companies built their traction through direct sales, clinic partnerships, or provider networks. AwaDoc got to 200 million queries through a personal brand and a free product, a very different growth engine, and one that raises different questions about durability.
The Questions AwaDoc Hasn’t Answered
AwaDoc has not disclosed institutional funding, and its business model currently appears to rely on Egemba’s personal brand and free WhatsApp access rather than a defined revenue stream. That absence of a disclosed monetisation plan is the clearest accountability question hanging over the platform’s growth. A quarter-billion queries is a genuine distribution achievement, particularly without ad spend, but scale on a free consumer health product does not by itself answer how the company sustains itself.
There is also the matter of oversight. AI-generated medical guidance delivered at population scale is likely to draw regulatory attention in Nigeria, whether from the Medical and Dental Council of Nigeria or the National Agency for Food and Drug Administration and Control, particularly if the platform’s claims about catching cancers through community screening start attracting the kind of scrutiny that comes with success. Data privacy is a related concern: health information shared over WhatsApp, even with encryption in transit, still has to be stored, processed, and potentially used to train the underlying AI system somewhere, and AwaDoc has not detailed what that pipeline looks like or who has access to it.
Egemba’s brand recognition got AwaDoc to 200 million queries. It will not, by itself, answer what the company does with the data those queries generate, how it plans to fund the infrastructure needed to keep serving a growing user base for free, or how it survives once the novelty of a WhatsApp doctor wears off and a well-funded competitor decides to copy the model with venture backing behind it.
For now, AwaDoc’s growth adds another data point to a pattern seen elsewhere in Nigeria’s AI-driven health tooling, where founders are building products around infrastructure Nigerians already trust rather than asking them to adopt something new. Whether that trust converts into a sustainable business, or simply a very large, very engaged free user base, is the question AwaDoc has yet to answer publicly.
